Compare BioNano Genomics Inc (BNGO) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Funko Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Funko Inc trades at $5.82 (market cap $310.19M). The key difference: Funko Inc is far larger — about 23.5× BioNano Genomics Inc's market cap, and Funko Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | FNKO | |
|---|---|---|
Market Cap | $13.20M | $310.19M |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $5.88 |
52-Week Low | $1.09 | $2.46 |
Enterprise Value | $15.81M | $555.22M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
FNKO trades at $5.69, up 1.97% with a bullish technical signal. Recent earnings beat expectations, yet the company reported a net loss of $67.36M in 2025. Revenue declined to $908.21M, but Q1 2026 showed improvement. Analyst consensus is mixed with 42.86% buy ratings. Cash flow trends are stabilizing, though negative profitability and high debt remain concerns.
Outlook hinges on execution of new product launches and cost management. Opportunities include brand strength and collectibles demand, but risks involve sustained losses, competitive pressure, and leverage. The stock presents a speculative growth play with significant turnaround requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
